- From: Eric Prud'hommeaux <eric@w3.org>
- Date: Tue, 21 Feb 2012 12:25:09 -0500
- To: w3c semweb hcls <public-semweb-lifesci@w3.org>
http://www.w3.org/2012/02/21-HCLS-minutes
[1]W3C
HCLS IG weekly: HCLS Pharmceutical in Clinical Research
21 Feb 2012
See also: [2]IRC log
Attendees
Present
Regrets
Chair
Vijay Bulusu
Scribe
ericP
Contents
* [3]Topics
1. [4]Vijay introduction
2. [5]Systems Biology for Drug Discovery
3. [6]Pharmacogenomics
4. [7]recruitment
5. [8]task force for rendering experimental information in an
open manner
* [9]Summary of Action Items
__________________________________________________________________
Vijay introduction
vbulusu: work in pharma
... invited by ericP to chair HCLS
... the cochairs and ericP discussed domain-specific calls for:
... .. interest to industry
... .. task force coodination
... there are two TFs in this focus:
... .. Systems Bio, chair: Helena Deus
... .. Pharmacogenomics, chair: Michel Dumontier
... looking for new ideas and use cases for these task forces
... will discuss a new task force for which I'm recruiting members
[10]Systems Biology for Drug Discovery
Helena: in Bio, many things go wrong at the pathway level
... e.g. signally pathway failures result in cancer
... so we'll look at data made available by TCGA
... RDF-izing the 8.3TB of TCGA is unreallistic
... instead we'll take data from 8 or 9 interesting proteins
... annotate the proteins with results [from TCGA]
... we need to look for TCGA resources and extract the 8 or 9 target
proteins
... first telco this week
... at the beginning, we'll be recruiting participants
... i've heard lots of interest
vbulusu: who do you have alread?
Helena: Jun Zao, ericP, Michael Miller (Institute for Systems Bio)
... hoping to recruit more bioinformatisists (as opposed to computer
geeks)
vbulusu: overlap with Sylventa's [11]BEL Framework?
Helena: there's a lot of overlap. expect to use their vocabs
... they're not annotating experimental data as far as i know
... michel demo'd SBML last week. should be relevent
ericP: Ted Slater described thinking of BEL in terms of a surface
syntax for RDF
ACTION: ericP to connect Ted Slater to Helena [recorded in
[12]http://www.w3.org/2012/02/21-HCLS-minutes.html#action01]
ACTION: ericP to connect Dave Hau to Helena [recorded in
[13]http://www.w3.org/2012/02/21-HCLS-minutes.html#action02]
mscottm2: Sylventa said they wanted to put BEL forward as a standard.
have they come to W3C?
ericP: they spoke about the openness in a presentation at the Cambridge
Semantic Web Gathering
Helena: my current wiki page is about recruitment
... people in this group expect to work bottom-up
... people say what they expect to achieve
michel: would like to see some structure, expected outcomes
Helena: i can add vision and goals to the wiki
vbulusu: adding the members will help
... do you need pharma folks?
Helena: desparately
vbulusu: bioinformatics and systems bio focus?
Helena: the bioinformatics is just how to glue stuff together
... exploring our models to see if we can learn stuff about the biology
ACTION: vbulusu to recruit in pharma for Systems Biology for Drug
Discovery [recorded in
[14]http://www.w3.org/2012/02/21-HCLS-minutes.html#action03]
michel: IO-Informatics might be interested
Helena: will reach out to Eric Gombocz
Pharmacogenomics
michel: we'll be looking at data related to pharmacogenomics
... e.g.
... .. patient stratification
... .. risk assessment
... .. dosing
... gathering related data, e.g.:
... .. clinical trial outcome
... .. efficacy
... we can marshal data from e.g. PharmGKB, or clinical trial
... wherever we can map genotype to phenotype
... idea is that we have a pharmacogenomics KB
... i got clinical annotation from PharmGKB
... PGKB license issue:
... .. you need to apply for access
... .. you can't redistribute
... maybe we can negotiate, but barring that, we can make available the
[triplifying] scripts
... we want to ask questions of the KB, with inference
... will support Clinical Decision Support
... we have folks from:
... .. mayo clinic
... .. variety of academic institutions
... missing industry, e.g. those interested in clinical trials or FDA
[,EMA] submissions, adverse event reporting
vbulusu: looking at use cases, have you looked at how to select a
smaller set of use cases?
michel: this [wiki] list is from the relevent TMO use cases
... some from IO-Informatics, and mscottm2 had breast cancer use cases
... so yes, we need to identify a small set
... potentially, each individual can set up a use case which drives
their personal interests
... i expect significant overlap due to the paucity of data
... gene expression, DBSNP, performance of (anti-rejection) drugs
ericP: feel free to be a tyrant
vbulusu: pharma focused on precision medicine
... mostly these folks would be interested in joining the HCLS
community where it can give them quick answers
recruitment
michel: we can ask industry what they need done, and peridically get
sanity checks
... but in the end, we want assurances of adoption
mscottm2: great if you can find someone in a hospital or pharma setting
who's not expecting a shrink-wrapped solution
... get them to bring us interesting problems
... most folks in those settings don't see the prob with working in
monolithic applications
<mscottm2> someone who can bring a problem for us to solve and become a
sort of 'client'
Helena: have you looked at pharmacoglycomics?
michel: looked at some sugars when i was an undergrad
... know folks at bioCanada who look at e.g. qualitiy of peptides ...
Helena: if you know the glycosylation pattern, you can predict binding
task force for rendering experimental information in an open manner
vbulusu: in 2009, [15]Pistoia started an Electronic Lab Notebook
working group to exploit the info captured in (different) ELNs
... also to share info in the pharma with other organizations
... looking at what they've done, they worked for a year trying to
create ELN standards so that e.g. CambridgeSoft data could work with
Exceleris
vbulusu: they stopped in early 2011 when some members didn't adopt and
proposed standards
... need is still out there.
... pharmas need to exchange with Clinical Research Organizations
... every pharma will say they need standards in this space
... expect to start with medicinal chemistry, not biology
<mscottm2> ericP: access control in ELN for example for CROs, capture
somethings in BEL framework.
[16]strawman research pipeline document
<michel>
[17]http://www.sciencedirect.com/science/article/pii/S1359644609000737
michel: met Jeremy Fray (S'Hampton) has been working on chem lab
notebooks
... he's got a representation for synthetic chemistry
... track whether you are doing stuff in the right order, and what are
the values you're obtaining
<mscottm2> Michel mentions Peter Murray-Rust / Cambridge (Open
Knowledge Foundation) in the context of patents
michel: Peter Murray Rust validates patents by seeing if the chemical
processes follow a single transformation
vbulusu: looked at Rust, and Jeremy's work is definitely in line. good
connections
michel: i don't think Jeremy focuses on inferencing; just capture for
later SPARQL query
... BEL may be more focused on inferencing
a(foo) upregulates b(c(bar)) .
Summary of Action Items
[NEW] ACTION: ericP to connect Dave Hau to Helena [recorded in
[18]http://www.w3.org/2012/02/21-HCLS-minutes.html#action02]
[NEW] ACTION: ericP to connect Ted Slater to Helena [recorded in
[19]http://www.w3.org/2012/02/21-HCLS-minutes.html#action01]
[NEW] ACTION: vbulusu to recruit in pharma for Systems Biology for Drug
Discovery [recorded in
[20]http://www.w3.org/2012/02/21-HCLS-minutes.html#action03]
[End of minutes]
__________________________________________________________________
Minutes formatted by David Booth's [21]scribe.perl version 1.136
([22]CVS log)
$Date: 2012/02/21 17:22:00 $
__________________________________________________________________
References
1. http://www.w3.org/
2. http://www.w3.org/2012/02/21-HCLS-irc
3. http://www.w3.org/2012/02/21-HCLS-minutes#agenda
4. http://www.w3.org/2012/02/21-HCLS-minutes#item01
5. http://www.w3.org/2012/02/21-HCLS-minutes#item02
6. http://www.w3.org/2012/02/21-HCLS-minutes#item03
7. http://www.w3.org/2012/02/21-HCLS-minutes#item04
8. http://www.w3.org/2012/02/21-HCLS-minutes#item05
9. http://www.w3.org/2012/02/21-HCLS-minutes#ActionSummary
10. http://www.w3.org/wiki/HCLSIG/SysBio
11. http://selventa.com/technology/bel-framework
12. http://www.w3.org/2012/02/21-HCLS-minutes.html#action01
13. http://www.w3.org/2012/02/21-HCLS-minutes.html#action02
14. http://www.w3.org/2012/02/21-HCLS-minutes.html#action03
15. http://www.pistoiaalliance.org/
16. http://www.w3.org/2012/hcls-resources/pipeline.svg
17. http://www.sciencedirect.com/science/article/pii/S1359644609000737
18. http://www.w3.org/2012/02/21-HCLS-minutes.html#action02
19. http://www.w3.org/2012/02/21-HCLS-minutes.html#action01
20. http://www.w3.org/2012/02/21-HCLS-minutes.html#action03
21. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm
22. http://dev.w3.org/cvsweb/2002/scribe/
23. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/
24. http://www.w3.org/2012/02/21-HCLS-minutes.html
25. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm
--
-ericP
Received on Tuesday, 21 February 2012 17:25:45 UTC